GEN Exclusives

More »

Insight & Intelligence™

Back to Item »

Dendreon’s $70M Investment in Production Capabilities Could Woo Firms without Similar Expertise

If cell-based immune therapy Provenge receives FDA sanction, it may corner a large market share and expand the company’s prospects.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?